Hyaluronic acid-graphene oxide quantum dots nanoconjugate as dual purpose drug delivery and therapeutic agent in meta-inflammation.
Adipose tissue inflammation
Graphene oxide quantum dots
Hepatic steatosis
Hyaluronic acid
Meta-inflammation
Metformin
Nanocomposite
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
01 Aug 2023
01 Aug 2023
Historique:
received:
21
03
2023
accepted:
21
07
2023
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
1
8
2023
Statut:
epublish
Résumé
Type 2 diabetes mellitus (T2DM) predominantly considered a metabolic disease is now being considered an inflammatory disease as well due to the involvement of meta-inflammation. Obesity-induced adipose tissue inflammation (ATI) is one of the earliest phenomena in the case of meta-inflammation, leading to the advent of insulin resistance (IR) and T2DM. The key events of ATI are orchestrated by macrophages, which aggravate the inflammatory state in the tissue upon activation, ultimately leading to systemic chronic low-grade inflammation and Non-Alcoholic Steatohepatitis (NASH) through the involvement of proinflammatory cytokines. The CD44 receptor on macrophages is overexpressed in ATI, NASH, and IR. Therefore, we developed a CD44 targeted Hyaluronic Acid functionalized Graphene Oxide Quantum Dots (GOQD-HA) nanocomposite for tissue-specific delivery of metformin. Metformin-loaded GOQD-HA (GOQD-HA-Met) successfully downregulated the expression of proinflammatory cytokines and restored antioxidant status at lower doses than free metformin in both palmitic acid-induced RAW264.7 cells and diet induced obese mice. Our study revealed that the GOQD-HA nanocarrier enhanced the efficacy of Metformin primarily by acting as a therapeutic agent apart from being a drug delivery platform. The therapeutic properties of GOQD-HA stem from both HA and GOQD having anti-inflammatory and antioxidant properties respectively. This study unravels the function of GOQD-HA as a targeted drug delivery option for metformin in meta-inflammation where the nanocarrier itself acts as a therapeutic agent.
Identifiants
pubmed: 37528408
doi: 10.1186/s12951-023-02015-w
pii: 10.1186/s12951-023-02015-w
pmc: PMC10394801
doi:
Substances chimiques
Hyaluronic Acid
9004-61-9
Nanoconjugates
0
graphene oxide
0
Antioxidants
0
Cytokines
0
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Subventions
Organisme : Department of Biotechnology, Ministry of Science and Technology, India
ID : BT/PR25080/NER/95/999/2017
Informations de copyright
© 2023. The Author(s).
Références
Langmuir. 2022 May 3;38(17):5040-5051
pubmed: 34096296
Acta Biomater. 2013 Dec;9(12):9243-57
pubmed: 23958782
Cartilage. 2019 Jan;10(1):43-52
pubmed: 29429372
Diabetologia. 2013 Apr;56(4):925-36
pubmed: 23370526
Bio Protoc. 2017 Jul 05;7(13):e2372
pubmed: 34541114
Trends Mol Med. 2008 Dec;14(12):539-49
pubmed: 18977694
J Pharm Pharmacol. 2017 Feb;69(2):143-150
pubmed: 28033667
Infect Dis Rep. 2010 Jan 1;2(1):
pubmed: 21390243
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):744-756
pubmed: 29437575
Drug Deliv. 2018 Nov;25(1):766-772
pubmed: 29536778
Proc Natl Acad Sci U S A. 2012 May 1;109(18):7049-54
pubmed: 22499789
Mol Pharm. 2013 Oct 7;10(10):3736-44
pubmed: 24007260
Mediators Inflamm. 2022 May 29;2022:2408598
pubmed: 35677735
J Biol Chem. 1999 Oct 22;274(43):30353-6
pubmed: 10521409
Biomaterials. 2015;53:341-8
pubmed: 25890732
Circ Res. 2005 May 13;96(9):939-49
pubmed: 15890981
Methods Enzymol. 1990;186:421-31
pubmed: 2233309
Diabetes. 2015 Jun;64(6):2028-41
pubmed: 25552600
J Nanobiotechnology. 2019 Dec 16;17(1):122
pubmed: 31842876
Hepatology. 2002 Feb;35(2):373-9
pubmed: 11826411
Biotechnol Appl Biochem. 2022 Jun;69(3):1068-1079
pubmed: 33932249
Nat Rev Endocrinol. 2017 Nov;13(11):633-643
pubmed: 28799554
J Control Release. 2021 Jun 10;334:275-289
pubmed: 33930479
Diabetes Care. 2006 May;29(5):1130-9
pubmed: 16644654
Front Mol Biosci. 2022 Dec 22;9:1049620
pubmed: 36619171
Nature. 2006 Dec 14;444(7121):875-80
pubmed: 17167476
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1147-1156
pubmed: 28450292
J Immunol. 2005 Mar 1;174(5):3032-40
pubmed: 15728517
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Diabetologia. 2017 Sep;60(9):1577-1585
pubmed: 28776086
ACS Biomater Sci Eng. 2021 Dec 13;7(12):5541-5554
pubmed: 34802226
Sci Rep. 2019 Aug 19;9(1):12028
pubmed: 31427693
Adv Sci (Weinh). 2018 Mar 04;5(5):1700595
pubmed: 29876205
Carbohydr Polym. 2023 Jan 1;299:120134
pubmed: 36876772
PLoS One. 2013;8(3):e58417
pubmed: 23505504
Diabetes. 2015 Mar;64(3):867-75
pubmed: 25294945
Nat Rev Dis Primers. 2015 Jul 23;1:15019
pubmed: 27189025
J Clin Invest. 2011 Jun;121(6):2094-101
pubmed: 21633177
J Clin Invest. 2006 Nov;116(11):3015-25
pubmed: 17053832
Heliyon. 2022 Mar 13;8(3):e09099
pubmed: 35309393
PLoS One. 2014 Mar 17;9(3):e91111
pubmed: 24638078
ACS Appl Mater Interfaces. 2017 Apr 12;9(14):12241-12252
pubmed: 28322544
J Hepatol. 2017 Aug;67(2):328-338
pubmed: 28323124
Trends Mol Med. 2001 May;7(5):213-21
pubmed: 11325633
J Control Release. 2018 Jun 10;279:89-98
pubmed: 29649530
Nat Med. 2019 Dec;25(12):1822-1832
pubmed: 31806905
J Nanobiotechnology. 2020 Oct 2;18(1):142
pubmed: 33008457
Adv Food Nutr Res. 2014;72:137-176
pubmed: 25081082
J Colloid Interface Sci. 2022 Nov 15;626:768-774
pubmed: 35820212
Adv Drug Deliv Rev. 2008 Dec 14;60(15):1615-26
pubmed: 18840489
Small. 2023 Mar 4;:e2207335
pubmed: 36871144
Cell. 1990 Jun 29;61(7):1303-13
pubmed: 1694723
Hypertension. 2006 Jun;47(6):1183-8
pubmed: 16636195
ACS Nano. 2017 Jun 27;11(6):5785-5799
pubmed: 28463501
Mikrochim Acta. 2017 Dec 18;185(1):66
pubmed: 29594582
Gastroenterol Clin North Am. 2016 Dec;45(4):639-652
pubmed: 27837778
Adv Healthc Mater. 2014 Aug;3(8):1261-71
pubmed: 24652715
Int J Biol Macromol. 2021 Jan 1;166:166-178
pubmed: 33172616
Cells. 2016 Mar 18;5(1):
pubmed: 26999213
Carbohydr Polym. 2021 Jun 1;261:117889
pubmed: 33766375
Int J Appl Basic Med Res. 2013 Jan;3(1):55-63
pubmed: 23776841
J Biomed Mater Res B Appl Biomater. 2023 May;111(5):1121-1132
pubmed: 36727427
World J Gastrointest Oncol. 2020 Jan 15;12(1):66-76
pubmed: 31966914
BMC Vet Res. 2021 Sep 25;17(1):315
pubmed: 34563196
Biomed Mater. 2021 Jul 05;16(5):
pubmed: 34157704
Adv Mater. 2011 Mar 25;23(12):H41-56
pubmed: 21394792
J Proteomics. 2022 Apr 15;257:104512
pubmed: 35139396
RSC Adv. 2022 May 11;12(22):14167-14174
pubmed: 35558858
ACS Appl Mater Interfaces. 2014 Aug 13;6(15):11882-90
pubmed: 25000539
Chemosphere. 2023 Aug;332:138848
pubmed: 37156291
Curr Drug Deliv. 2022;19(1):93-103
pubmed: 34126895
Int J Mol Sci. 2016 Dec 11;17(12):
pubmed: 27973438
Circ Res. 2020 May 22;126(11):1549-1564
pubmed: 32437299
ACS Appl Mater Interfaces. 2015 May 27;7(20):10935-43
pubmed: 25939643
Nat Rev Drug Discov. 2016 Sep;15(9):639-660
pubmed: 27256476
Adv Mater. 2019 Aug;31(34):e1803549
pubmed: 30773699
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
J Clin Invest. 2017 Jan 3;127(1):55-64
pubmed: 28045404
Endocrinology. 2020 Sep 1;161(9):
pubmed: 32790834
Eur J Pharm Sci. 2019 Apr 1;131:1-8
pubmed: 30735819
Nanomedicine (Lond). 2023 Jan;18(2):109-123
pubmed: 36853798
Biomed Res Int. 2014;2014:605135
pubmed: 25114913